Skip to main content
Top
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

SNP rs3202538 in 3′UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population

Authors: Yaxiang Shi, Xuan Chen, Biao Xi, Xiaowen Yu, Jun Ouyang, Chunxia Han, Yucheng Qin, Defeng Wu, Hong Shen

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background/aims

ErbB3 is an oncogene which has proliferation and metastasis promotion effects by several signaling pathways. However, the individual expression difference regulated by miRNA was almost still unknown. We focused on the miRNAs associated SNPs in the 3′-UTR of ErbB3 to investigate the further relationship of the SNPs with miRNAs among Chinese gastric cancer (GC) patients.

Methods

We performed case–control study including 851 GC patients and 799 cancer-free controls. Genotyping, real-time PCR assay, cell transfection, the dual luciferase reporter assay, western-blot, cell proliferation and trans-well based cell invasion assay were used to investigate the effects of the SNP on ErbB3 expression. Moreover, a 5-years-overall survival and relapse free survival were investigated between different genotypes.

Results

We found that patients suffering from Helicobacter pylori (Hp.) infection indicated to be the susceptible population by comparing with controls. Besides, SNP rs3202538 (G/T) in ErbB3 3′-UTR was involved in the occurrence of GC by acting as tumor risk factors. SNP rs3202538 (G/T) could be regulated by both miR-204 and miR-211 which caused an upregulation of ErbB3 in patients. Furthermore, the carriers of T genotype was related to the significantly high expression of ErbB3, and to big tumor size, poor differentiation as well as the high probability of metastasis. Both miR-211 and miR-204 can significantly decrease cell proliferation, metastasis as well as downstream AKT activation through G but not T allele of ErbB3 3′UTR. Moreover, the SNP of G/T was associated with shorter survival of post-surgery GC patients with 5 years of follow up study.

Conclusion

In conclusion, our findings have shown that the SNP rs3202538 (G/T) in ErbB3 3′-UTR acted as promotion factors in the GC development through disrupting the regulatory role of miR-204 and miR-211 in ErbB3 expression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gastric Cancer Treatment (PDQ(R)). Health professional version. PDQ cancer information summaries. Bethesda (MD). 2002. Gastric Cancer Treatment (PDQ(R)). Health professional version. PDQ cancer information summaries. Bethesda (MD). 2002.
2.
go back to reference Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191–7.CrossRefPubMed Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191–7.CrossRefPubMed
3.
go back to reference Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol. 2014;232:219–29.CrossRefPubMed Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol. 2014;232:219–29.CrossRefPubMed
4.
go back to reference Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.CrossRefPubMed Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.CrossRefPubMed
5.
go back to reference Letelier P, Garcia P, Leal P, et al. miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol. 2014;7:1849–67.PubMedPubMedCentral Letelier P, Garcia P, Leal P, et al. miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol. 2014;7:1849–67.PubMedPubMedCentral
6.
go back to reference Momose K, Minami A, Shimono Y, et al. miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3 signaling. Genes Cells. 2013;18:195–202.CrossRefPubMed Momose K, Minami A, Shimono Y, et al. miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3 signaling. Genes Cells. 2013;18:195–202.CrossRefPubMed
7.
go back to reference Wang S, Huang J, Lyu H, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013;4:e556.CrossRefPubMedPubMedCentral Wang S, Huang J, Lyu H, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013;4:e556.CrossRefPubMedPubMedCentral
8.
10.
go back to reference Koutras A, Kotoula V, Fountzilas G. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. Pharmacogenomics. 2015;16:79–94.CrossRefPubMed Koutras A, Kotoula V, Fountzilas G. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. Pharmacogenomics. 2015;16:79–94.CrossRefPubMed
11.
go back to reference Mishra PJ, Mishra PJ, Banerjee D, et al. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle. 2008;7:853–8.CrossRefPubMed Mishra PJ, Mishra PJ, Banerjee D, et al. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle. 2008;7:853–8.CrossRefPubMed
12.
go back to reference de Jong VM, Zaldumbide A, van der Slik AR, et al. Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants. Genes Immun. 2013;14:58–61.CrossRefPubMed de Jong VM, Zaldumbide A, van der Slik AR, et al. Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants. Genes Immun. 2013;14:58–61.CrossRefPubMed
13.
go back to reference Sentinelli F, Filippi E, Fallarino M, et al. The 3′-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. Nutr Metab Cardiovasc Dis. 2006;16:345–52.CrossRefPubMed Sentinelli F, Filippi E, Fallarino M, et al. The 3′-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. Nutr Metab Cardiovasc Dis. 2006;16:345–52.CrossRefPubMed
14.
go back to reference Amin DN, Sergina N, Lim L, et al. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012;447:417–25.CrossRefPubMedPubMedCentral Amin DN, Sergina N, Lim L, et al. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012;447:417–25.CrossRefPubMedPubMedCentral
15.
go back to reference Wang L, Yuan H, Li Y, et al. The role of HER3 in gastric cancer. Biomed Pharmacother. 2014;68:809–12.CrossRefPubMed Wang L, Yuan H, Li Y, et al. The role of HER3 in gastric cancer. Biomed Pharmacother. 2014;68:809–12.CrossRefPubMed
16.
go back to reference Wu G, Qin XQ, Guo JJ, et al. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7:1449–58.PubMedPubMedCentral Wu G, Qin XQ, Guo JJ, et al. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7:1449–58.PubMedPubMedCentral
17.
go back to reference Han S, Meng Y, Tong Q, et al. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. MAbs. 2014;6:403–8.CrossRefPubMed Han S, Meng Y, Tong Q, et al. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. MAbs. 2014;6:403–8.CrossRefPubMed
18.
go back to reference Yun C, Gang L, Rongmin G, et al. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer. Mol Carcinog. 2015;54:1700–9.CrossRefPubMed Yun C, Gang L, Rongmin G, et al. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer. Mol Carcinog. 2015;54:1700–9.CrossRefPubMed
19.
go back to reference Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40:841–9.CrossRefPubMedPubMedCentral Levy C, Khaled M, Iliopoulos D, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40:841–9.CrossRefPubMedPubMedCentral
20.
go back to reference Song GQ, Zhao Y. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration. Tumour Biol. 2015;36:5001–9.CrossRefPubMed Song GQ, Zhao Y. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration. Tumour Biol. 2015;36:5001–9.CrossRefPubMed
21.
go back to reference Ye L, Wang H, Liu B. miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumour Biol. 2016;37:1151–7.CrossRefPubMed Ye L, Wang H, Liu B. miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumour Biol. 2016;37:1151–7.CrossRefPubMed
22.
go back to reference Cai C, Ashktorab H, Pang X, et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS ONE. 2012;7:e29750.CrossRefPubMedPubMedCentral Cai C, Ashktorab H, Pang X, et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS ONE. 2012;7:e29750.CrossRefPubMedPubMedCentral
23.
go back to reference Naraparaju K, Kolla V, Zhuang T, et al. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget. 2016;7:15977–85.CrossRefPubMedPubMedCentral Naraparaju K, Kolla V, Zhuang T, et al. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget. 2016;7:15977–85.CrossRefPubMedPubMedCentral
24.
go back to reference Zhou X, Li L, Su J, et al. Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4. PLoS ONE. 2014;9:e101457.CrossRefPubMedPubMedCentral Zhou X, Li L, Su J, et al. Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4. PLoS ONE. 2014;9:e101457.CrossRefPubMedPubMedCentral
25.
go back to reference Liu Z, Long J, Du R, et al. miR-204 regulates the EMT by targeting snai1 to suppress the invasion and migration of gastric cancer. Tumour Biol. 2016;37:8327–35.CrossRefPubMed Liu Z, Long J, Du R, et al. miR-204 regulates the EMT by targeting snai1 to suppress the invasion and migration of gastric cancer. Tumour Biol. 2016;37:8327–35.CrossRefPubMed
26.
go back to reference Zhang L, Wang X, Chen P. MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial–mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer. 2013;13:290.CrossRefPubMedPubMedCentral Zhang L, Wang X, Chen P. MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial–mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer. 2013;13:290.CrossRefPubMedPubMedCentral
Metadata
Title
SNP rs3202538 in 3′UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population
Authors
Yaxiang Shi
Xuan Chen
Biao Xi
Xiaowen Yu
Jun Ouyang
Chunxia Han
Yucheng Qin
Defeng Wu
Hong Shen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0449-z

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine